By JONEL ALECCIA A quarter-size device that tracks the rise and fall of sugar in your blood is the latest source of hope — and hype — in the growing buzz around wearable health ...

FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and ...

The researchers observed “significant” weight regain at eight, 12, and 20 weeks after discontinuation. They deduced that most patients gain back the weight they initially lost for an average of 20 ...